This is a special type of medicine called an immunotoxin. It's used to treat a specific type of cancer called acute myeloid leukemia. It works by targeting cancer cells and delivering a drug to kill them.
Every report comes from a Lived member, sent anonymously.
Have you tried Mylotarg (Gemtuzumab) for AML (Acute Myeloid Leukemia)?
Gemtuzumab ozogamicin, sold as Mylotarg, is a targeted cancer medicine for acute myeloid leukemia (AML), a fast-growing cancer of the blood-forming cells in the bone marrow. It is used only when the leukemia cells carry a surface protein called CD33, which a lab test of the leukemia cells checks for. It has two approved roles. For newly diagnosed AML, it can be added to standard intensive chemotherapy (daunorubicin and cytarabine) in adults and in children 1 month and older. Adults with newly diagnosed AML can also receive it on its own; this approach was studied in older adults who were not well enough for intensive chemotherapy or did not want it. For AML that has come back after treatment (relapsed) or did not respond to it (refractory), it can be given on its own to adults and children 2 years and older.
Gemtuzumab is an antibody-drug conjugate: a laboratory-made antibody joined to a powerful cell-killing drug called calicheamicin. The antibody works as a guide. It attaches to CD33 on leukemia cells, and the cell then draws the antibody and its attached drug inside. There, calicheamicin is released and breaks both strands of the cell's DNA, which stops the cell from dividing and causes it to die. This targeting concentrates the drug on cells that carry CD33, but it is still a form of chemotherapy. It lowers blood counts for weeks and can damage the liver, which is why those are its main risks.
Gemtuzumab is given by a cancer care team as an intravenous (IV) infusion that takes about 2 hours. The dose is calculated from body size, and the schedule depends on the situation. With intensive chemotherapy for newly diagnosed AML, adults usually receive it on days 1, 4 and 7 of the first (induction) cycle and once in each of two later (consolidation) cycles; it is not given if a second induction cycle is needed. Children receive a single dose in up to two of their chemotherapy cycles. Used alone for relapsed or refractory AML, it is one course of three doses. Used alone for newly diagnosed AML in adults, two induction doses can be followed by up to eight monthly doses, which in the main trial were given as outpatient treatment. About an hour before each infusion, people receive acetaminophen and an antihistamine, then a corticosteroid shortly before it starts, to lower the chance of an infusion reaction. The team checks vital signs during the infusion and for at least an hour afterward. Liver tests and blood counts are checked before each dose, and a dose may be delayed, skipped or stopped if they have not recovered enough.
Because gemtuzumab is given with or as chemotherapy, many side effects resemble chemotherapy's: fever, infections, nausea, vomiting, constipation, headache, rash, mouth sores, loss of appetite and raised liver enzymes on blood tests. Blood counts fall for weeks, which raises the risk of infection, including fever when white cells are very low (febrile neutropenia). The care team will explain exactly what to do if a fever develops during that time. Infusion reactions can happen during the infusion or up to 24 hours afterward. Fever, chills, rash or breathing problems after leaving the treatment area should be reported to the care team right away. Bleeding is a central risk because platelets, the cells that help blood clot, can stay low for a long time, and some bleeding in trials was fatal, including bleeding in the brain. Report new bruising, nosebleeds, bleeding gums, or blood in urine or stool promptly. Bleeding that will not stop, or a sudden severe headache, confusion or weakness, needs emergency care. Gemtuzumab carries the FDA's most serious (boxed) warning for liver damage, including veno-occlusive disease (VOD, also called sinusoidal obstruction syndrome), in which small veins in the liver become blocked. VOD can be fatal. In trials most cases began within a few weeks of a dose, but some appeared months later, including after a stem cell transplant. Rapid weight gain, a swelling belly, or pain or tenderness under the right ribs should be reported to the care team right away.
People who have had a severe allergic reaction to gemtuzumab or any of its ingredients should not receive it. The risk of VOD is higher in people who already have moderate or severe liver problems, in people treated with gemtuzumab after a stem cell transplant, and in people who go on to a transplant after it. In the main adult trial, a gap of at least 2 months between the last dose and a transplant was recommended. Gemtuzumab can harm a developing baby, so a pregnancy test is done before starting. Women who could become pregnant should use effective birth control during treatment and for at least 6 months after the last dose, and men with a partner who could become pregnant should do so for at least 3 months after. Breastfeeding should be avoided during treatment and for at least 1 month after the last dose. Animal studies suggest it may reduce fertility in both men and women, which is worth raising before treatment begins. The label lists no specific drug interactions. However, related drugs carrying the same toxin have prolonged the QT interval, a measure on an electrocardiogram (ECG) of how long the heart takes to recharge between beats; a longer QT can raise the risk of abnormal heart rhythms. People with a history of QT problems, electrolyte (blood salt) imbalances, or who take other medicines known to prolong QT may need an ECG and electrolyte checks before and during treatment.
Treatment involves close monitoring: blood counts and blood chemistry are checked at least three times a week until they recover, along with regular liver tests. Low counts can last weeks, and platelets stayed low for longer when gemtuzumab was added to chemotherapy than with chemotherapy alone. What gemtuzumab mainly adds to chemotherapy is a lower chance of the leukemia coming back, rather than a higher chance of reaching remission in the first place. In the main adult trial (ages 50 to 70), adding it lengthened the typical time before treatment failure, relapse or death from about 9.5 months to 17.3 months, though overall survival was not clearly different in that trial. A pooled analysis of five adult trials found a survival benefit that was clearest when the leukemia had favorable genetic features, smaller with intermediate features, and absent with adverse (high-risk) genetic features. Because those genetic test results often arrive after treatment has started, the team may reconsider whether to continue gemtuzumab once they are known. Used alone in older adults who could not have intensive chemotherapy, it extended median survival modestly, from 3.6 to 4.9 months compared with supportive care. In adults whose AML had relapsed for the first time, about one in four reached complete remission after a single course. For many people, gemtuzumab is one step in a longer plan that may include further chemotherapy or a stem cell transplant.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Mylotarg (Gemtuzumab), what you've noticed, or ask the community a question.